Depixus, a pioneer in the field of intereactomics, has been awarded the prestigious Ignite Award by the Society for Laboratory Automation and Screening (SLAS) at their annual International Conference and Exhibition in Boston, MA. The award was presented to the company in recognition of their groundbreaking MAGNA™ technology, which is based on magnetic force spectroscopy and enables high-throughput analysis of dynamic biomolecular interactions.
Depixus was selected as one of just 16 companies to participate in the SLAS2024 Innovation AveNEW program, which is a dedicated area for start-ups and emerging companies within the conference. From this group, eight companies were chosen as finalists for the Ignite Award. MAGNA One, which is based on this technology, offers real-time measurements from thousands of individual molecules simultaneously, making it particularly useful for exploring challenging targets such as RNA and protein-protein interactions. This technology provides valuable insights into disease mechanisms and accelerates the development of novel therapeutics.
CEO Gordon Hamilton expressed his excitement about winning the Ignite Award, highlighting Depixus’ innovative technology and its potential to impact the understanding and treatment of diseases where new treatments are urgently needed. He emphasized that this achievement marks a significant moment for Depixus as they continue to grow and expand their offerings in this rapidly evolving field.
Chief Commercial Officer Steve Klose added that he believes that this award coincides with Depixus’ launch of their technology access program and commercial rollout of MAGNA One, marking an exciting time for the company. He believes that this recognition will help drive growth and expansion in Depixus’ customer base as more businesses seek to harness its innovative capabilities to advance their own research efforts.
For more information about Depixus or their MAGNA One instrument, please visit depixus.com or contact Steve Klose at firstname.lastname@example.org